Pacira BioSciences (NASDAQ:PCRX) Trading Up 2.7%

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) rose 2.7% on Tuesday . The stock traded as high as $27.32 and last traded at $27.24. Approximately 113,521 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 489,085 shares. The stock had previously closed at $26.53.

Analyst Ratings Changes

A number of brokerages recently weighed in on PCRX. Royal Bank of Canada decreased their price objective on Pacira BioSciences from $53.00 to $45.00 and set an "outperform" rating for the company in a research note on Friday, March 1st. JPMorgan Chase & Co. began coverage on Pacira BioSciences in a research note on Thursday, March 7th. They set an "overweight" rating and a $45.00 price objective for the company. Raymond James began coverage on Pacira BioSciences in a research note on Wednesday, December 20th. They set an "outperform" rating and a $42.00 price objective for the company. Needham & Company LLC restated a "buy" rating and set a $45.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, April 9th. Finally, TheStreet upgraded Pacira BioSciences from a "d+" rating to a "c" rating in a research note on Thursday, February 29th. Eleven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $49.50.

Pacira BioSciences Stock Up 1.3 %

The business has a fifty day moving average price of $29.24 and a two-hundred day moving average price of $29.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.24 and a quick ratio of 4.17. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of 33.77 and a beta of 0.76.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its earnings results on Thursday, February 29th. The company reported $0.71 EPS for the quarter, hitting the consensus estimate of $0.71. The firm had revenue of $181.24 million for the quarter, compared to analyst estimates of $180.60 million. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. On average, equities analysts expect that Pacira BioSciences, Inc. will post 2.18 earnings per share for the current year.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now directly owns 140,384 shares of the company's stock, valued at $4,165,193.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the firm's stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $30.60, for a total value of $2,754,000.00. Following the sale, the director now directly owns 22,127 shares of the company's stock, valued at $677,086.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gary W. Pace sold 1,066 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the completion of the transaction, the director now owns 140,384 shares in the company, valued at approximately $4,165,193.28. The disclosure for this sale can be found here. 6.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pacira BioSciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. ICA Group Wealth Management LLC purchased a new position in shares of Pacira BioSciences in the fourth quarter valued at approximately $30,000. Financial Freedom LLC purchased a new position in Pacira BioSciences during the fourth quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. lifted its position in Pacira BioSciences by 96.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company's stock worth $36,000 after buying an additional 583 shares in the last quarter. Neo Ivy Capital Management purchased a new position in Pacira BioSciences during the second quarter worth approximately $44,000. Finally, Torno Capital LLC purchased a new position in Pacira BioSciences during the fourth quarter worth approximately $51,000. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.